Delivery Order SPE2DB20D1100-SPE2DB24FD1A1

Award Date 8/5/24
Potential Completion Date 8/6/24
Potential Value $4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,524.36, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Quillivant XR 25 mg/5 ml suspension in 60 ml bottles, a prescription medication. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $1,172.71 Firm Fixed Price Delivery Order is for the supply of Quillivant XR 25 mg/5 ml suspension, a prescription medication. The contract has an ultimate completion date of July 22, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,005.90 firm fixed-price delivery order is for the supply of Quillivant XR 25 mg/5 ml suspension, a prescription medication. The contract has an ultimate completion date of January 29, 2025 and was awarded on January 28, 2025. This contract is part of a larger Indefinite Delivery Contract (IDC) valued at...
This is a $2,967.19 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a prescription medication. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This is a $5,021.42 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is for the supply of Quillivant XR 25 mg/5 ml suspension, a prescription medication. The order has an ultimate completion date of March 3, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle...
This federal contract award, valued at $1,682.18, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Quillivant XR 25 mg/5 ml suspension, a prescription medication. The contract type is a Delivery Order with a Firm Fixed Price pricing structure, and the ultimate completion date is October 18, 2023. This contract award is part of a larger Indefinite Delivery...
This federal contract award, valued at $1,577.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order contract for the supply of Quillivant XR, a 25 mg/5 ml suspension medication. The contract is a firm fixed-price arrangement with an ultimate completion date of April 16, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
The U.S. Defense Logistics Agency (DLA) awarded a $1,347.88 firm-fixed-price delivery order to AmerisourceBergen Drug Corp. for the supply of 150 mL bottles of the pharmaceutical product Quillivant XR 25 mg/5 mL suspension. This order is a part of a larger indefinite delivery contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is for the delivery of Quillivant XR 25 mg/5 ml suspension, a prescription medication, with a total ceiling value of $1,971.30 and a completion date of January 16, 2025. The contract is a Delivery Order under a broader Indefinite Delivery Contract (IDC) valued at $999,999,999 and awarded to AmerisourceBergen by the DLA,...
This federal contract award, valued at $2,711.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Quillivant XR 25 mg/5 ml suspension in 60 ml containers, with a performance period extending to April 9, 2025. This delivery order contract is a firm fixed-price arrangement and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a substantial...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB24FD1A1
    Delivery Order

This federal contract award, valued at $3,966.18, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Quillivant XR 25 mg/5 ml suspension medication. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 through December 2025. This contract supports the supply of a diverse range of medical commodities, including prescription drugs, to military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is expected to be completed by August 6, 2024.

Generated 11/4/24, 10:29 AM